Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism

AIM: To evaluate the plasma level of circulating heptocyte growth factor (HGF) in patients with comorbidity of post-infarction chronic heart failure (CHF), type 2 diabetes mellitus (T2DM) and obesity. We also aimed to assess possible correlations between HGF levels and parameters of carbohydrate and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatiana Nikolaevna Kochegura, P I Makarevich, A G Ovchinnikov, L V Zhigunova, Elena Leonidovna Lahova, Marina Vladimirovna Shestakova, F T Ageev, Elena Viktorovna Parfenova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	type 2 diabetes mellitus chronic heart failure circulating hepatocyte growth factor Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/8f104d8b011a41e589949dc791464f62
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f104d8b011a41e589949dc791464f62
record_format	dspace
spelling	oai:doaj.org-article:8f104d8b011a41e589949dc791464f622021-11-14T09:00:18ZCirculating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism2072-03512072-037810.14341/2072-0351-3752https://doaj.org/article/8f104d8b011a41e589949dc791464f622013-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/3752https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378AIM: To evaluate the plasma level of circulating heptocyte growth factor (HGF) in patients with comorbidity of post-infarction chronic heart failure (CHF), type 2 diabetes mellitus (T2DM) and obesity. We also aimed to assess possible correlations between HGF levels and parameters of carbohydrate and lipid metabolism, as well as myocardial functional characteristics and classic biochemical severity markers for CHF.17Сахар ный диабет КардиологияСахарный диабет. 2013;(2):17-25 MATERIALS AND METHODS: We enrolled 100 patients for participation in this study, including the following subgroups: 20 individuals with- out cardiovascular and glycemic disorders, 30 patients with CHF, 25 patients with CHF/T2DM comorbidity and 25 diabetic patients with no signs of heart failure. Quantitative plasma HGF analysis was performed with enzyme-linked immunosorbent assay (ELISA). RESULTS: Plasma HGF was elevated both in patients with CHF and T2DM as measured against healthy control group. The elevation was most prominent in patients with CHF/T2DM comorbidity and was found to correlate with HbA1c level (r=0.52, p=0.03). Plasma HGF also correlated with BMI (r=0.42, p=0007) in a unified study group, though we observed no statistically significant difference between subgroups with a trend toward higher HGF in obese patients with CHF/T2DM comorbidity (626.1?254.1 pg/ml vs 742.0?210.7 pg/ml respectively; p >0.05). Interestingly, plasma HGF was also significantly higher in controls with BMI >30 km/m2 (324.1?107.7 pg/ml vs 436.9?112.3 pg/ml, p=0.03).Circulating HGF correlated with plasma levels of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) and such structural and functional myocardial characteristics as left atrial size and maximum volume along with left ventricular ejection fraction (EF), end-diastolic volume (EDV) and end-diastolic dimension (EDD). CONCLUSION: These findings suggest that HGF may potentially serve as a prediction marker for unfavorable myocardial remodeling and poor prognosis in CHF patients with T2DM and obesity, though this possibility should be further investigated in follow-up studies.Tatiana Nikolaevna KocheguraP I MakarevichA G OvchinnikovL V ZhigunovaElena Leonidovna LahovaMarina Vladimirovna ShestakovaF T AgeevElena Viktorovna ParfenovaEndocrinology Research Centrearticletype 2 diabetes mellituschronic heart failurecirculating hepatocyte growth factorNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 2, Pp 17-25 (2013)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus chronic heart failure circulating hepatocyte growth factor Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus chronic heart failure circulating hepatocyte growth factor Nutritional diseases. Deficiency diseases RC620-627 Tatiana Nikolaevna Kochegura P I Makarevich A G Ovchinnikov L V Zhigunova Elena Leonidovna Lahova Marina Vladimirovna Shestakova F T Ageev Elena Viktorovna Parfenova Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
description	AIM: To evaluate the plasma level of circulating heptocyte growth factor (HGF) in patients with comorbidity of post-infarction chronic heart failure (CHF), type 2 diabetes mellitus (T2DM) and obesity. We also aimed to assess possible correlations between HGF levels and parameters of carbohydrate and lipid metabolism, as well as myocardial functional characteristics and classic biochemical severity markers for CHF.17Сахар ный диабет КардиологияСахарный диабет. 2013;(2):17-25 MATERIALS AND METHODS: We enrolled 100 patients for participation in this study, including the following subgroups: 20 individuals with- out cardiovascular and glycemic disorders, 30 patients with CHF, 25 patients with CHF/T2DM comorbidity and 25 diabetic patients with no signs of heart failure. Quantitative plasma HGF analysis was performed with enzyme-linked immunosorbent assay (ELISA). RESULTS: Plasma HGF was elevated both in patients with CHF and T2DM as measured against healthy control group. The elevation was most prominent in patients with CHF/T2DM comorbidity and was found to correlate with HbA1c level (r=0.52, p=0.03). Plasma HGF also correlated with BMI (r=0.42, p=0007) in a unified study group, though we observed no statistically significant difference between subgroups with a trend toward higher HGF in obese patients with CHF/T2DM comorbidity (626.1?254.1 pg/ml vs 742.0?210.7 pg/ml respectively; p >0.05). Interestingly, plasma HGF was also significantly higher in controls with BMI >30 km/m2 (324.1?107.7 pg/ml vs 436.9?112.3 pg/ml, p=0.03).Circulating HGF correlated with plasma levels of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) and such structural and functional myocardial characteristics as left atrial size and maximum volume along with left ventricular ejection fraction (EF), end-diastolic volume (EDV) and end-diastolic dimension (EDD). CONCLUSION: These findings suggest that HGF may potentially serve as a prediction marker for unfavorable myocardial remodeling and poor prognosis in CHF patients with T2DM and obesity, though this possibility should be further investigated in follow-up studies.
format	article
author	Tatiana Nikolaevna Kochegura P I Makarevich A G Ovchinnikov L V Zhigunova Elena Leonidovna Lahova Marina Vladimirovna Shestakova F T Ageev Elena Viktorovna Parfenova
author_facet	Tatiana Nikolaevna Kochegura P I Makarevich A G Ovchinnikov L V Zhigunova Elena Leonidovna Lahova Marina Vladimirovna Shestakova F T Ageev Elena Viktorovna Parfenova
author_sort	Tatiana Nikolaevna Kochegura
title	Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
title_short	Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
title_full	Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
title_fullStr	Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
title_full_unstemmed	Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
title_sort	circulating hepatocyte growth factor (hgf) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism
publisher	Endocrinology Research Centre
publishDate	2013
url	https://doaj.org/article/8f104d8b011a41e589949dc791464f62
work_keys_str_mv	AT tatiananikolaevnakochegura circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT pimakarevich circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT agovchinnikov circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT lvzhigunova circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT elenaleonidovnalahova circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT marinavladimirovnashestakova circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT ftageev circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism AT elenaviktorovnaparfenova circulatinghepatocytegrowthfactorhgfinpatientswithcomorbidityofchronicheartfailuretype2diabetesmellitusandimpairedlipidmetabolism
_version_	1718429592740429824

Circulating hepatocyte growth factor (HGF) in patients with comorbidity of chronic heart failure, type 2 diabetes mellitus and impaired lipid metabolism

Ejemplares similares